Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls.

Winter MP, Koziński M, Kubica J, Aradi D, Siller-Matula JM.

Postepy Kardiol Interwencyjnej. 2015;11(4):259-80. doi: 10.5114/pwki.2015.55596. Epub 2015 Jan 12. Review.

2.

Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics.

Chan SL, Samaranayake N, Ross CJ, Toh MT, Carleton B, Hayden MR, Teo YY, Dissanayake VH, Brunham LR.

Pharmacogenet Genomics. 2016 Jan;26(1):28-39. doi: 10.1097/FPC.0000000000000182.

3.

Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014.

Byrne RA, Joner M, Kastrati A.

Eur Heart J. 2015 Dec 14;36(47):3320-31. doi: 10.1093/eurheartj/ehv511. Epub 2015 Sep 28. Review.

4.

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Yang Y, Lewis JP, Hulot JS, Scott SA.

Expert Opin Drug Metab Toxicol. 2015;11(10):1599-617. doi: 10.1517/17425255.2015.1068757. Epub 2015 Jul 14. Review.

PMID:
26173871
5.

Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics.

Beitelshees AL, Voora D, Lewis JP.

Pharmgenomics Pers Med. 2015 Feb 9;8:43-61. doi: 10.2147/PGPM.S52900. eCollection 2015. Review.

6.

Early stent thrombosis. Aetiology, treatment, and prognosis.

Tyczyński P, Karcz MA, Kalińczuk L, Fronczak A, Witkowski A.

Postepy Kardiol Interwencyjnej. 2014;10(4):221-5. doi: 10.5114/pwki.2014.46761. Epub 2014 Nov 17. No abstract available.

7.

Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.

Siller-Matula JM, Lang IM, Neunteufl T, Kozinski M, Maurer G, Linkowska K, Grzybowski T, Kubica J, Jilma B.

PLoS One. 2014 Jul 22;9(7):e102701. doi: 10.1371/journal.pone.0102701. eCollection 2014.

8.

The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis.

Floyd CN, Mustafa A, Ferro A.

PLoS One. 2014 Jul 2;9(7):e101518. doi: 10.1371/journal.pone.0101518. eCollection 2014.

9.

Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery.

Sousa-Uva M, Storey R, Huber K, Falk V, Leite-Moreira AF, Amour J, Al-Attar N, Ascione R, Taggart D, Collet JP; ESC Working Group on Cardiovascular Surgery and ESC Working Group on Thrombosis.

Eur Heart J. 2014 Jun 14;35(23):1510-4. doi: 10.1093/eurheartj/ehu158. Epub 2014 Apr 18. No abstract available.

10.

Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study.

Zhang L, Li Y, Jing QM, Wang XZ, Ma YY, Wang G, Xu B, Gao RL, Han YL; CREATE Investigators.

J Interv Cardiol. 2014 Apr;27(2):119-26. doi: 10.1111/joic.12104. Epub 2014 Mar 12.

11.

Antiplatelet drug interactions with proton pump inhibitors.

Scott SA, Owusu Obeng A, Hulot JS.

Expert Opin Drug Metab Toxicol. 2014 Feb;10(2):175-89. doi: 10.1517/17425255.2014.856883. Epub 2013 Nov 9. Review.

12.

The genetic basis for survivorship in coronary artery disease.

Dungan JR, Hauser ER, Qin X, Kraus WE.

Front Genet. 2013 Sep 27;4:191. doi: 10.3389/fgene.2013.00191. eCollection 2013.

13.

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.

14.

Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?

Perry CG, Shuldiner AR.

J Hum Genet. 2013 Jun;58(6):339-45. doi: 10.1038/jhg.2013.41. Epub 2013 May 23. Review.

15.

Towards personalized medicine based on platelet function testing for stent thrombosis patients.

Godschalk TC, Hackeng CM, Ten Berg JM.

Thrombosis. 2012;2012:617098. doi: 10.1155/2012/617098. Epub 2012 Dec 25.

16.

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.

Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Gurbel PA, Shuldiner AR.

Pharmacogenet Genomics. 2013 Jan;23(1):1-8. doi: 10.1097/FPC.0b013e32835aa8a2.

17.

ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis.

Su J, Xu J, Li X, Zhang H, Hu J, Fang R, Chen X.

PLoS One. 2012;7(10):e46366. doi: 10.1371/journal.pone.0046366. Epub 2012 Oct 9.

18.

Stent thrombosis: incidence, predictors and new technologies.

Buchanan GL, Basavarajaiah S, Chieffo A.

Thrombosis. 2012;2012:956962. doi: 10.1155/2012/956962. Epub 2012 Mar 11.

19.

Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.

Reny JL, Combescure C, Daali Y, Fontana P; PON1 Meta-Analysis Group.

J Thromb Haemost. 2012 Jul;10(7):1242-51. doi: 10.1111/j.1538-7836.2012.04756.x. Review.

20.

Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.

Martis S, Peter I, Hulot JS, Kornreich R, Desnick RJ, Scott SA.

Pharmacogenomics J. 2013 Aug;13(4):369-77. doi: 10.1038/tpj.2012.10. Epub 2012 Apr 10.

Items per page

Supplemental Content

Write to the Help Desk